LCTX
Lineage Cell Therapeutics, Inc.
Key Financials
Gross Profit
$8.3M
↓ 40.8%
Revenue
$14.6M
↑ 53.2%
Operating Income
$-36619000
↓ 70.5%
Net Income
$-63533000
↓ 241.4%
EPS (Diluted)
$-0.28
↓ 211.1%
Shareholders' Equity
$44.5M
↓ 43.2%
Total Liabilities
$69.2M
↑ 91.2%
Cash & Equivalents
$40.8M
↓ 10.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LCTX |
| Company Name | Lineage Cell Therapeutics, Inc. |
| CIK | 876343 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | CA |
| Phone | 5105213390 |